Pasireotide versus octreotide in acromegaly: a head-to-head superiority study.

Colao A, Bronstein MD, Freda P, Gu F, Shen CC, Gadelha M, Fleseriu M, van der Lely AJ, Farrall AJ, Hermosillo Reséndiz K, Ruffin M, Chen Y, Sheppard M

The Journal of clinical endocrinology and metabolism13 Jan 2014Cited by 294 (Europe PMC)

PMID24423324PMCIDPMC3965714DOI10.1210/jc.2013-2480PepBankPUB-24423324

Read at source PubMedAsk about this study

Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanRandomized controlled trialEfficacy outcome
In acromegaly, biochemical control occurred in 19.2% with octreotide LAR versus 31.3% with pasireotide LAR (P = .007).
In plain wordsIn acromegaly, octreotide LAR achieved biochemical control less often than pasireotide LAR.
Peptide
Octreotide
Outcome
DecreaseBiochemical control
Study
n = 358
Comparator
Pasireotide LAR
Analysis
Primary
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
20 mg/28 days, with optional titration to 30 mg at months 3 and 7 · 12 monthsAs given in this study (human).
Measurements
Biochemical control rate
19.2%
octreotide LAR
Biochemical control rate
31.3%
pasireotide LAR
P value
0.007
octreotide LAR versus pasireotide LAR
Source sentences
Summary
Biochemical control was achieved by significantly more pasireotide LAR patients than octreotide LAR patients (31.3% vs 19.2%; P = .007; 35.8% vs 20.9% when including patients with IGF-1 below the lower normal limit).
5 context sentences(design, population, supporting numbers)
Summary · context
The main outcome measure was the proportion of patients in each treatment arm with biochemical control (GH <2.5 μg/L and normal IGF-1) at month 12.
Summary · context
We conducted a prospective, randomized, double-blind study at 84 sites in 27 countries.
Summary · context
A total of 358 patients with medically naive acromegaly (GH >5 μg/L or GH nadir ≥1 μg/L after an oral glucose tolerance test (OGTT) and IGF-1 above the upper limit of normal) were enrolled.
Summary · context
Patients received pasireotide LAR 40 mg/28 days (n = 176) or octreotide LAR 20 mg/28 days (n = 182) for 12 months.
Summary · context
At months 3 and 7, titration to pasireotide LAR 60 mg or octreotide LAR 30 mg was permitted, but not mandatory, if GH ≥2.5μg/L and/or IGF-1 was above the upper limit of normal.
Report a problemFND-2442332401
02HumanRandomized controlled trialEfficacy outcome
In acromegaly, biochemical control occurred in 31.3% with pasireotide LAR versus 19.2% with octreotide LAR (P = .007).
In plain wordsIn acromegaly, pasireotide LAR achieved biochemical control more often than octreotide LAR.
Peptide
Pasireotide
Outcome
IncreaseBiochemical control
Study
n = 358
Comparator
Octreotide LAR
Analysis
Primary
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
40 mg/28 days, with optional titration to 60 mg at months 3 and 7 · 12 monthsAs given in this study (human).
Measurements
Biochemical control rate
19.2%
octreotide LAR
Biochemical control rate
31.3%
pasireotide LAR
P value
0.007
octreotide LAR versus pasireotide LAR
Source sentences
Summary
Biochemical control was achieved by significantly more pasireotide LAR patients than octreotide LAR patients (31.3% vs 19.2%; P = .007; 35.8% vs 20.9% when including patients with IGF-1 below the lower normal limit).
5 context sentences(design, population, supporting numbers)
Summary · context
The main outcome measure was the proportion of patients in each treatment arm with biochemical control (GH <2.5 μg/L and normal IGF-1) at month 12.
Summary · context
We conducted a prospective, randomized, double-blind study at 84 sites in 27 countries.
Summary · context
A total of 358 patients with medically naive acromegaly (GH >5 μg/L or GH nadir ≥1 μg/L after an oral glucose tolerance test (OGTT) and IGF-1 above the upper limit of normal) were enrolled.
Summary · context
Patients received pasireotide LAR 40 mg/28 days (n = 176) or octreotide LAR 20 mg/28 days (n = 182) for 12 months.
Summary · context
At months 3 and 7, titration to pasireotide LAR 60 mg or octreotide LAR 30 mg was permitted, but not mandatory, if GH ≥2.5μg/L and/or IGF-1 was above the upper limit of normal.
Report a problemFND-2442332402
03HumanRandomized controlled trialEfficacy outcome
In acromegaly, control including below-normal IGF-1 occurred in 20.9% with octreotide LAR versus 35.8% with pasireotide LAR.
In plain wordsIn acromegaly, control including low IGF-1 occurred less often with octreotide LAR than pasireotide LAR.
Peptide
Octreotide
Outcome
DecreaseBiochemical control including low IGF-1
Study
n = 358
Comparator
Pasireotide LAR
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
20 mg/28 days, with optional titration to 30 mg at months 3 and 7 · 12 monthsAs given in this study (human).
Measurements
Biochemical control rate including IGF-1 below lower normal limit
20.9%
octreotide LAR
Biochemical control rate including IGF-1 below lower normal limit
35.8%
pasireotide LAR
Source sentences
Summary
Biochemical control was achieved by significantly more pasireotide LAR patients than octreotide LAR patients (31.3% vs 19.2%; P = .007; 35.8% vs 20.9% when including patients with IGF-1 below the lower normal limit).
4 context sentences(design, population, supporting numbers)
Summary · context
We conducted a prospective, randomized, double-blind study at 84 sites in 27 countries.
Summary · context
A total of 358 patients with medically naive acromegaly (GH >5 μg/L or GH nadir ≥1 μg/L after an oral glucose tolerance test (OGTT) and IGF-1 above the upper limit of normal) were enrolled.
Summary · context
Patients received pasireotide LAR 40 mg/28 days (n = 176) or octreotide LAR 20 mg/28 days (n = 182) for 12 months.
Summary · context
At months 3 and 7, titration to pasireotide LAR 60 mg or octreotide LAR 30 mg was permitted, but not mandatory, if GH ≥2.5μg/L and/or IGF-1 was above the upper limit of normal.
Report a problemFND-2442332403
04HumanRandomized controlled trialEfficacy outcome
In acromegaly, control including below-normal IGF-1 occurred in 35.8% with pasireotide LAR versus 20.9% with octreotide LAR.
In plain wordsIn acromegaly, control including low IGF-1 occurred more often with pasireotide LAR than octreotide LAR.
Peptide
Pasireotide
Outcome
IncreaseBiochemical control including low IGF-1
Study
n = 358
Comparator
Octreotide LAR
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
40 mg/28 days, with optional titration to 60 mg at months 3 and 7 · 12 monthsAs given in this study (human).
Measurements
Biochemical control rate including IGF-1 below lower normal limit
20.9%
octreotide LAR
Biochemical control rate including IGF-1 below lower normal limit
35.8%
pasireotide LAR
Source sentences
Summary
Biochemical control was achieved by significantly more pasireotide LAR patients than octreotide LAR patients (31.3% vs 19.2%; P = .007; 35.8% vs 20.9% when including patients with IGF-1 below the lower normal limit).
4 context sentences(design, population, supporting numbers)
Summary · context
We conducted a prospective, randomized, double-blind study at 84 sites in 27 countries.
Summary · context
A total of 358 patients with medically naive acromegaly (GH >5 μg/L or GH nadir ≥1 μg/L after an oral glucose tolerance test (OGTT) and IGF-1 above the upper limit of normal) were enrolled.
Summary · context
Patients received pasireotide LAR 40 mg/28 days (n = 176) or octreotide LAR 20 mg/28 days (n = 182) for 12 months.
Summary · context
At months 3 and 7, titration to pasireotide LAR 60 mg or octreotide LAR 30 mg was permitted, but not mandatory, if GH ≥2.5μg/L and/or IGF-1 was above the upper limit of normal.
Report a problemFND-2442332404
05HumanRandomized controlled trialEfficacy outcome
In acromegaly, normal IGF-1 occurred in 23.6% with octreotide LAR versus 38.6% with pasireotide LAR (P = .002).
In plain wordsIn acromegaly, normal IGF-1 occurred less often with octreotide LAR than pasireotide LAR.
Peptide
Octreotide
Outcome
DecreaseNormal IGF-1
Study
n = 358
Comparator
Pasireotide LAR
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
20 mg/28 days, with optional titration to 30 mg at months 3 and 7 · 12 monthsAs given in this study (human).
Measurements
Normal IGF-1 rate
23.6%
octreotide LAR
Normal IGF-1 rate
38.6%
pasireotide LAR
P value
0.002
octreotide LAR versus pasireotide LAR
Source sentences
Summary
In pasireotide LAR and octreotide LAR patients, respectively, 38.6% and 23.6% (P = .002) achieved normal IGF-1, and 48.3% and 51.6% achieved GH <2.5 μg/L.
4 context sentences(design, population, supporting numbers)
Summary · context
We conducted a prospective, randomized, double-blind study at 84 sites in 27 countries.
Summary · context
A total of 358 patients with medically naive acromegaly (GH >5 μg/L or GH nadir ≥1 μg/L after an oral glucose tolerance test (OGTT) and IGF-1 above the upper limit of normal) were enrolled.
Summary · context
Patients received pasireotide LAR 40 mg/28 days (n = 176) or octreotide LAR 20 mg/28 days (n = 182) for 12 months.
Summary · context
At months 3 and 7, titration to pasireotide LAR 60 mg or octreotide LAR 30 mg was permitted, but not mandatory, if GH ≥2.5μg/L and/or IGF-1 was above the upper limit of normal.
Report a problemFND-2442332405
06HumanRandomized controlled trialEfficacy outcome
In acromegaly, normal IGF-1 occurred in 38.6% with pasireotide LAR versus 23.6% with octreotide LAR (P = .002).
In plain wordsIn acromegaly, normal IGF-1 occurred more often with pasireotide LAR than octreotide LAR.
Peptide
Pasireotide
Outcome
IncreaseNormal IGF-1
Study
n = 358
Comparator
Octreotide LAR
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
40 mg/28 days, with optional titration to 60 mg at months 3 and 7 · 12 monthsAs given in this study (human).
Measurements
Normal IGF-1 rate
23.6%
octreotide LAR
Normal IGF-1 rate
38.6%
pasireotide LAR
P value
0.002
octreotide LAR versus pasireotide LAR
Source sentences
Summary
In pasireotide LAR and octreotide LAR patients, respectively, 38.6% and 23.6% (P = .002) achieved normal IGF-1, and 48.3% and 51.6% achieved GH <2.5 μg/L.
4 context sentences(design, population, supporting numbers)
Summary · context
We conducted a prospective, randomized, double-blind study at 84 sites in 27 countries.
Summary · context
A total of 358 patients with medically naive acromegaly (GH >5 μg/L or GH nadir ≥1 μg/L after an oral glucose tolerance test (OGTT) and IGF-1 above the upper limit of normal) were enrolled.
Summary · context
Patients received pasireotide LAR 40 mg/28 days (n = 176) or octreotide LAR 20 mg/28 days (n = 182) for 12 months.
Summary · context
At months 3 and 7, titration to pasireotide LAR 60 mg or octreotide LAR 30 mg was permitted, but not mandatory, if GH ≥2.5μg/L and/or IGF-1 was above the upper limit of normal.
Report a problemFND-2442332406
07HumanRandomized controlled trialEfficacy outcome
In acromegaly, GH <2.5 μg/L occurred in 51.6% with octreotide LAR versus 48.3% with pasireotide LAR.
In plain wordsIn acromegaly, low GH occurred numerically more often with octreotide LAR than pasireotide LAR.
Peptide
Octreotide
Outcome
IncreaseGH below threshold
Study
n = 358
Comparator
Pasireotide LAR
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
20 mg/28 days, with optional titration to 30 mg at months 3 and 7 · 12 monthsAs given in this study (human).
Measurements
GH <2.5 µg/L rate
51.6%
octreotide LAR
GH <2.5 µg/L rate
48.3%
pasireotide LAR
Source sentences
Summary
In pasireotide LAR and octreotide LAR patients, respectively, 38.6% and 23.6% (P = .002) achieved normal IGF-1, and 48.3% and 51.6% achieved GH <2.5 μg/L.
4 context sentences(design, population, supporting numbers)
Summary · context
We conducted a prospective, randomized, double-blind study at 84 sites in 27 countries.
Summary · context
A total of 358 patients with medically naive acromegaly (GH >5 μg/L or GH nadir ≥1 μg/L after an oral glucose tolerance test (OGTT) and IGF-1 above the upper limit of normal) were enrolled.
Summary · context
Patients received pasireotide LAR 40 mg/28 days (n = 176) or octreotide LAR 20 mg/28 days (n = 182) for 12 months.
Summary · context
At months 3 and 7, titration to pasireotide LAR 60 mg or octreotide LAR 30 mg was permitted, but not mandatory, if GH ≥2.5μg/L and/or IGF-1 was above the upper limit of normal.
Report a problemFND-2442332407
08HumanRandomized controlled trialEfficacy outcome
In acromegaly, GH <2.5 μg/L occurred in 48.3% with pasireotide LAR versus 51.6% with octreotide LAR.
In plain wordsIn acromegaly, low GH occurred numerically less often with pasireotide LAR than octreotide LAR.
Peptide
Pasireotide
Outcome
DecreaseGH below threshold
Study
n = 358
Comparator
Octreotide LAR
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
40 mg/28 days, with optional titration to 60 mg at months 3 and 7 · 12 monthsAs given in this study (human).
Measurements
GH <2.5 µg/L rate
51.6%
octreotide LAR
GH <2.5 µg/L rate
48.3%
pasireotide LAR
Source sentences
Summary
In pasireotide LAR and octreotide LAR patients, respectively, 38.6% and 23.6% (P = .002) achieved normal IGF-1, and 48.3% and 51.6% achieved GH <2.5 μg/L.
4 context sentences(design, population, supporting numbers)
Summary · context
We conducted a prospective, randomized, double-blind study at 84 sites in 27 countries.
Summary · context
A total of 358 patients with medically naive acromegaly (GH >5 μg/L or GH nadir ≥1 μg/L after an oral glucose tolerance test (OGTT) and IGF-1 above the upper limit of normal) were enrolled.
Summary · context
Patients received pasireotide LAR 40 mg/28 days (n = 176) or octreotide LAR 20 mg/28 days (n = 182) for 12 months.
Summary · context
At months 3 and 7, titration to pasireotide LAR 60 mg or octreotide LAR 30 mg was permitted, but not mandatory, if GH ≥2.5μg/L and/or IGF-1 was above the upper limit of normal.
Report a problemFND-2442332408
09HumanRandomized controlled trialSafety outcome
In acromegaly, hyperglycemia-related events occurred in 21.7% with octreotide LAR versus 57.3% with pasireotide LAR.
In plain wordsIn acromegaly, high-blood-sugar events occurred less often with octreotide LAR than pasireotide LAR.
Peptide
Octreotide
Outcome
DecreaseHyperglycemia-related adverse events
Study
n: not reported in source
Comparator
Pasireotide LAR
Outcome group
Adverse events · Metabolic and weight
Studied dose
20 mg/28 days, with optional titration to 30 mg at months 3 and 7 · 12 monthsAs given in this study (human).
Measurements
Hyperglycemia-related adverse event rate
21.7%
octreotide LAR
Hyperglycemia-related adverse event rate
57.3%
pasireotide LAR
Source sentences
Summary
Hyperglycemia-related adverse events were more common with pasireotide LAR (57.3% vs 21.7%).
4 context sentences(design, population, supporting numbers)
Summary · context
We conducted a prospective, randomized, double-blind study at 84 sites in 27 countries.
Summary · context
A total of 358 patients with medically naive acromegaly (GH >5 μg/L or GH nadir ≥1 μg/L after an oral glucose tolerance test (OGTT) and IGF-1 above the upper limit of normal) were enrolled.
Summary · context
Patients received pasireotide LAR 40 mg/28 days (n = 176) or octreotide LAR 20 mg/28 days (n = 182) for 12 months.
Summary · context
At months 3 and 7, titration to pasireotide LAR 60 mg or octreotide LAR 30 mg was permitted, but not mandatory, if GH ≥2.5μg/L and/or IGF-1 was above the upper limit of normal.
Report a problemFND-2442332411
10HumanRandomized controlled trialSafety outcome
In acromegaly, hyperglycemia-related events occurred in 57.3% with pasireotide LAR versus 21.7% with octreotide LAR.
In plain wordsIn acromegaly, high-blood-sugar events occurred more often with pasireotide LAR than octreotide LAR.
Peptide
Pasireotide
Outcome
IncreaseHyperglycemia-related adverse events
Study
n: not reported in source
Comparator
Octreotide LAR
Outcome group
Adverse events · Metabolic and weight
Studied dose
40 mg/28 days, with optional titration to 60 mg at months 3 and 7 · 12 monthsAs given in this study (human).
Measurements
Hyperglycemia-related adverse event rate
21.7%
octreotide LAR
Hyperglycemia-related adverse event rate
57.3%
pasireotide LAR
Source sentences
Summary
Hyperglycemia-related adverse events were more common with pasireotide LAR (57.3% vs 21.7%).
4 context sentences(design, population, supporting numbers)
Summary · context
We conducted a prospective, randomized, double-blind study at 84 sites in 27 countries.
Summary · context
A total of 358 patients with medically naive acromegaly (GH >5 μg/L or GH nadir ≥1 μg/L after an oral glucose tolerance test (OGTT) and IGF-1 above the upper limit of normal) were enrolled.
Summary · context
Patients received pasireotide LAR 40 mg/28 days (n = 176) or octreotide LAR 20 mg/28 days (n = 182) for 12 months.
Summary · context
At months 3 and 7, titration to pasireotide LAR 60 mg or octreotide LAR 30 mg was permitted, but not mandatory, if GH ≥2.5μg/L and/or IGF-1 was above the upper limit of normal.
Report a problemFND-2442332412

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 2
27 Oct 2026, 16:36 UTC
Study data updated · source update from Europe PMC
Version 1
27 Oct 2026, 16:34 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.